1.13
-0.02 (-2.17%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cellectar Biosciences, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.67 |
Select this tab to load the latest available analysis.
|
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 6.91% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |